Corrigendum to: thinking ahead: developing biosynthetic blood to anticipate donor drought

This corrigendum contains corrections the article ‘Thinking ahead: developing biosynthetic blood to anticipate donor drought’ Cell & Gene Therapy Insights 2022; 8(11), 1561–1570; DOI: 10.18609/cgti.2022.227. In the version of this article initially published, it was stated that clinical trials for Hemarina M101 had been suspended. In fact, at the time of publication, Hemarina’s HEMO2life^® had just received CE approval for the preservation of kidney grafts for transplantation. The correction is listed in full below, and the amended article can be accessed here.

Please enter your email to access content Read now